Imaging-aided gene therapy using mesenchymal stem cells as target-delivery vehicle
US9498499B2 · kind B2 · utility
Inventors
Key dates
| Filing date | Apr 19, 2013 |
| Grant date | Nov 22, 2016 |
| Priority date | — |
| Expiry date | Apr 19, 2033 |
Classification
- Technology area (CPC C)Chemistry; Metallurgy
- CPC primaryC12N2502/99
- WIPO fieldPharmaceuticals
- WIPO sectorChemistry
Abstract
Compositions and methods of use thereof encompass engineered mesenchymal stem cells as a vehicle to deliver secreted tissue necrosis factor-RGD4C fusion polypeptides for tumor treatment, thereby reducing side effects of TNF. A reporter gene can be included in vector constructs to monitor the localization and viability of engineered MSCs after administration into a recipient animal. The genetically modified mesenchymal stem cell can comprise an expression cassette comprising a nucleic acid sequence operably linked to a gene expression promoter and encoding the heterologous fusion polypeptide comprising a tissue necrotic factor region and an integrin-binding region. Another aspect of the disclosure encompasses embodiments of a method of modulating the proliferation of a targeted population of tumor cells by delivering a population of the genetically modified mesenchymal stem cells to tumor cells, allowing the mesenchymal stem cells to express the heterologous polypeptide, thereby reducing the proliferative capacity of the tumor cells.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.